Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia

  • ACS Med Chem Lett. 2015 May 20;6(6):716-20. doi: 10.1021/acsmedchemlett.5b00181.
Susana Conde-Ceide  1 ,  Carlos M Martínez-Viturro  1 ,  Jesús Alcázar  1 ,  Pedro M Garcia-Barrantes  2 ,  Hilde Lavreysen  3 ,  Claire Mackie  3 ,  Paige N Vinson  4 ,  Jerri M Rook  4 ,  Thomas M Bridges  4 ,  J Scott Daniels  4 ,  Anton Megens  3 ,  Xavier Langlois  3 ,  Wilhelmus H Drinkenburg  3 ,  Abdellah Ahnaou  3 ,  Colleen M Niswender  4 ,  Carrie K Jones  4 ,  Gregor J Macdonald  3 ,  Thomas Steckler  3 ,  P Jeffrey Conn  4 ,  Shaun R Stauffer  4 ,  José Manuel Bartolomé-Nebreda  1 ,  Craig W Lindsley  4
Affiliations
  • 1. Neuroscience Medicinal Chemistry and Discovery Sciences Lead Discovery, Janssen Research and Development , Jarama 75A, 45007 Toledo, Spain.
  • 2. Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States.
  • 3. Neuroscience and Discovery Sciences ADME/Tox, Janssen Research and Development , Turnhoutseweg 30, B-2340 Beerse, Belgium.
  • 4. Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States ; Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States.
PMID: 26157544 DOI: 10.1021/acsmedchemlett.5b00181
Abstract

Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0409551/JNJ-46778212) was selected as a candidate for further development.

Keywords
4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine; JNJ-46778212; Positive allosteric modulator (PAM); VU0409551; metabotropic glutamate receptor 5 (mGlu5); schizophrenia.
Products